Inadequate Design Undermines the Negative Conclusion

Agreement: I Agree Body: Dear Editor This study’s conclusion that SGLT-2 inhibitors and GLP-1 receptor agonists provide no renal benefit in patients without albuminuria cannot be supported by its own design. A median follow-up of 32 months is far too short to detect the hard endpoint of creatinine doubling. With a baseline eGFR of 92 mL/min/1.73 m2 and an event rate of merely 1.3%, the analysis is severely underpowered. Furthermore, merging GLP-1 RAs and SGLT-2is into a single exposure class obs